Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamine SCHEMBL15764650 | 0.86 | HDAC1 (0.68) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| Hydroxyamine SCHEMBL2880441 | 0.86 | HDAC1 (0.68) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL2871316 | 0.85 | HDAC1 (0.76) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL7899314 | 0.84 | HDAC1 (0.72) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL15960887 | 0.82 | HDAC1 (0.49) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| Hydroxyamine SCHEMBL2880350 | 0.79 | HDAC1 (0.57) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL12396438 | 0.79 | FFAR1 (0.85) | FFAR1FFAR4TBXAS1 | |
| Hydroxyamine SCHEMBL2879083 | 0.78 | HDAC1 (0.74) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| Hydroxyamine SCHEMBL2880603 | 0.77 | HDAC1 (0.74) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| Hydroxyamine SCHEMBL15955464 | 0.76 | HDAC1 (0.76) | HDAC1HDAC6HDAC2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391605-B1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LTD (GB) | 2017-11-08 | — | — | EP | disclosed |
| US-9340503-B2 | Scriptaid isosteres and their use in therapy | KARUS THERAPEUTICS, LIMITED (GB) | 2016-05-17 | — | — | US | disclosed |
| US-20140235671-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2014-08-21 | — | — | US | disclosed |
| US-8748458-B2 | Scriptaid isosteres and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2014-06-10 | — | — | US | disclosed |
| US-20110305729-A1 | Scriptaid Isosteres and Their Use in Therapy | KARUS THERAPEUTICS LIMITED (GB) | 2011-12-15 | — | — | US | disclosed |
| EP-2391605-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | Karus Therapeutics Limited (GB) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086646-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235671-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | QARS1, C1QBP, QTRT1 | HDAC1 674/4885HDAC6 365/4885HDAC2 1110/4885 |
| US-20110305729-A1 | Scriptaid Isosteres and Their Use in Therapy | QARS1, C1QBP, C1S | HDAC1 598/4885HDAC6 293/4885HDAC2 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.